Dynavax Technologies Corporation
Dynavax Technologies Corporation, commonly referred to as Dynavax, is a prominent biopharmaceutical company headquartered in the United States. Founded in 1996, Dynavax has established itself in the immunotherapy sector, focusing on the development of innovative therapies for infectious diseases and cancer. The company is renowned for its flagship product, HEPLISAV-B, a unique hepatitis B vaccine that offers enhanced protection with a two-dose regimen. This product exemplifies Dynavax's commitment to advancing vaccine technology and improving patient outcomes. With a strong market position, Dynavax has achieved significant milestones, including successful collaborations and partnerships that bolster its research and development efforts. The company continues to expand its operational footprint, contributing to the evolving landscape of immunology and infectious disease management.
DitchCarbon Score
How does Dynavax Technologies Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dynavax Technologies Corporation's score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dynavax Technologies Corporation's reported carbon emissions
Dynavax Technologies Corporation, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges from the company, suggesting a lack of formal commitments to address carbon emissions at this time. As there is no emissions data available, it is important to note that Dynavax Technologies Corporation may still be evaluating its climate strategy or developing future initiatives. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from Dynavax, it remains unclear how they plan to engage with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dynavax Technologies Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
